Product
TCR reserved and Power3 Gene Knock-out Allogeneic CD19-targeting CAR-T cell
1 clinical trial
1 indication
Indication
Acute Lymphocytic LeukemiaClinical trial
A Phase 1/2 Single-center Study Evaluating the Safety and Efficacy of TCR Reserved and Power3 Gene Knock-out Allogeneic CD19-targeting CAR-T Cell Therapy in Adults With Refractory/Relapsed B-cell Acute Lymphoblastic LeukaemiaStatus: Recruiting, Estimated PCD: 2026-07-01